AI Article Synopsis
- COX-2 and 5-LOX enzymes are found to be overactive in esophageal squamous cell carcinoma (ESCC), prompting this study to explore how inhibiting these enzymes affects cancer growth.
- The inhibitors, Nimesulide (for COX-2) and AA861 (for 5-LOX), were shown to reduce cell growth and promote cell death, as well as decrease specific inflammatory substances (PGE(2) and LTB(4)).
- Animal tests revealed that treated tumors were significantly smaller, with lower cell proliferation rates, supporting the idea that using both inhibitors together might be more effective against ESCC than using either one alone.
Article Abstract
COX-2 and 5-LOX are up-regulated in ESCC. This study aims to determine the efficacy of COX-2 inhibitor, 5-LOX inhibitor and their combination on ESCC. Nimesulide can suppress cell growth and promote apoptosis, accompanied with a decrease of PGE(2) production. AA861 has the similar effect with a down-regulation of LTB(4). In animal experiment, the tumor volumes in drug-treated groups were significantly smaller with the lowest rates of Ki-67 positive cells. In conclusion, either COX-2 inhibitor or 5-LOX inhibitor can suppress ESCC. Dual inhibition of COX-2 and 5-LOX pathway may present a superior anticancer efficacy to either inhibition of COX-2 or 5-LOX alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canlet.2011.05.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!